脊髓小腦萎縮症(Spinocerebellar ataxia, SCA)，是群異質性體染色體顯性遺傳的神經退化性疾病，主要病徵包括共濟失調、癡呆、肌張力障礙及癲癇等，病理特徵主要是小腦萎縮。第17型脊髓小腦萎縮症(SCA17)是由於在TATA-binding protein (TBP)基因上有過度重複擴增的CAG/CAA序列重複所引起的一種多麩醯胺酸(polyglutamine, polyQ)疾病，TBP是三種RNA聚合酶轉錄起始的重要轉錄因子，多麩醯胺酸過長造成蛋白質錯誤折疊而堆積，並進而引發細胞損傷及退化，尤其以小腦的Purkinje cell特別明顯。組織蛋白去乙醯酶(Histone deacetylase, HDAC)會將組蛋白之乙醯基團移除而讓組蛋白更緊密的與DNA結合，抑制基因的轉錄，造成許多疾病，組織蛋白去乙醯酶抑制劑(HDACi)可以改善轉錄的抑制，並在一些神經退化性疾病中扮演神經保護的角色，我們建立SCA17小鼠小腦的初級細胞培養和小腦切片培養來篩選HDACi，並將有潛力的化合物進行動物行為實驗。在SCA17小鼠小腦的初級細胞培養中我們發現NC105和NC109可以增加Purkinje cell的神經突生長(neurite length)，在SCA17小鼠小腦的體外切片培養也看到TBP聚集有明顯的下降，因此用NC105和NC109進行小量動物行為的預試驗，我們發現SCA17小鼠的體重並沒有明顯受到藥物之改變，運動平衡改善上，NC105和NC109組別的小鼠在rotarod停留的時間有增加的趨勢，病理上我們發現SCA17小鼠Purkinje cell退化情形有得到改善，同時Histon H3與Histon H4乙醯化程度有明顯提高，我們也發現給予NC105和NC109的SCA17小鼠Purkinje cell TBP聚集的情形有明顯改善，因此我們認為NC105和NC109能抑制HDAC以改善轉錄的異常。進入了大量動物行為實驗之後，NC105及NC109之處理並不影響小鼠體重，也不影響小鼠的焦慮，但改善小鼠的運動協調能力，同時增加HSP的表現，NC109更能有效降低TBP不正常聚集，因此我們認為NC105和NC109是有潛力改善SCA17小鼠病徵的HDACi。

Spinocerebellar ataxia (SCA) is a group of heterogeneous autosomal dominant neurodegenerative diseases. Clinical symptoms include ataxia, dementia, dystonia, seizures, and significant cerebellum atrophy in pathology. Spinocerebellar ataxia type 17 (SCA17) is one type of SCAs. It is caused by CAA/CAG repeat segment of the TATA-binding protein (TBP) gene. TBP is a crucial transcription factors for all the three RNA polymerase in transcription initiation. The polyglutamine (polyQ)-expanded mutant TBP accumulates as aggregates in the cells and leads to cell degeneration, especially the cerebellar Purkinje neurons. Histone deacetylases (HDAC) make the histones more tightly bind to DNA by removing the acetyl groups from histones, which in turn suppresses the gene transcription and causes many diseases. HDAC inhibitors could alleviate transcription suppression and show neuroprotecive effect in several neurodegenerative diseases. We used the mouse cerebellar primary culture from the SCA17 transgenic mice established in our lab to screen HDAC inhibitors. The potential compounds were further applied for in vivo test. We found two HDAC inhibitors, NC105 and NC109, can increase Purkinje cell total neurite lengthon primary culture and decrease TBP aggregation on slice culture. These two HDAC inhibitors were applied to small-scale SCA17 mice to verify their efficacy in vivo. During the in vivo treatment, mouse body weight was not altered by HDACi treatment. In addition, mouse motor coordination was improved from the rotarod task evaluation. Our preliminary results show these two inhibitors alleviate Purkinje cell degeneration and increase histone acetylation. NC105 and NC109 treatment can also decrease TBP aggregation. These compounds might alleviate the transcriptional dysfunction of SCA17 through inhibition of HDAC. These two HDAC inhibitors also could significant improved mouse motor coordination from the behavior evaluation for large scale animal test. In sum, NC105 and NC109 show significant effect in vitro and improve motor coordination and reduce neuron degeneration of SCA17 transgenic mice. The result suggests that these two HDACi could be potential HDAC inhibitors for SCA17 treatment.

Altman J, Bayer SA (1996) Development of the cerebellar system in relation to its evolution, structure, and functions. Boca Raton: CRC Press.
Apps R, Garwicz M (2005) Anatomical and physiological foundations of cerebellar information processing. Nature reviews Neuroscience 6:297-311.
Bijangi-Vishehsaraei K, Saadatzadeh MR, Huang S, Murphy MP, Safa AR (2010) 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Molecular and cellular biochemistry 342:133-142.
Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, Petrucelli L (2012) Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Human molecular genetics 21:2936-2945.
Cendelin J, Voller J, Vozeh F (2010) Ataxic gait analysis in a mouse model of the olivocerebellar degeneration. Behavioural brain research 210:8-15.
Chang YC, Lin CY, Hsu CM, Lin HC, Chen YH, Lee-Chen GJ, Su MT, Ro LS, Chen CM, Hsieh-Li HM (2011) Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17. Journal of neurochemistry 118:288-303.
Chen J, Sidhu A (2005) The role of D1 dopamine receptors and phospho-ERK in mediating cytotoxicity. Commentary. Neurotoxicity research 7:179-181.
Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends in neurosciences 32:591-601.
Dieni S, Rees S (2002) Distribution of brain-derived neurotrophic factor and TrkB receptor proteins in the fetal and postnatal hippocampus and cerebellum of the guinea pig. The Journal of comparative neurology 454:229-240.
Di Prospero NA, Fischbeck KH (2005) Therapeutics development for triplet repeat expansion diseases. Nature reviews Genetics 6:756-765.
Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:3571-3583.
Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The international journal of biochemistry & cell biology 33:637-668.
El Idrissi A, Boukarrou L, Heany W, Malliaros G, Sangdee C, Neuwirth L (2009) Effects of taurine on anxiety-like and locomotor behavior of mice. Advances in experimental medicine and biology 643:207-215.
Figiel M, Szlachcic WJ, Switonski PM, Gabka A, Krzyzosiak WJ (2012) Mouse models of polyglutamine diseases: review and data table. Part I. Molecular neurobiology 46:393-429.
Furuya S, Makino A, Hirabayashi Y (1998) An improved method for culturing cerebellar Purkinje cells with differentiated dendrites under a mixed monolayer setting. Brain research Brain research protocols 3:192-198.
Gimenez-Cassina A, Lim F, Diaz-Nido J (2007) Gene transfer into Purkinje cells using herpesviral amplicon vectors in cerebellar cultures. Neurochemistry international 50:181-188.
Gottesfeld JM, Rusche JR, Pandolfo M (2013) Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. Journal of neurochemistry 126 Suppl 1:147-154.
Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A (2011) Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. Journal of Alzheimer's disease : JAD 26:187-197.
Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. British journal of cancer 108:748-754.
Gruol DL, Franklin CL (1987) Morphological and physiological differentiation of Purkinje neurons in cultures of rat cerebellum. The Journal of neuroscience : the official journal of the Society for Neuroscience 7:1271-1293.
Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America 100:4389-4394.
Harding AE (1982) The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the 'the Drew family of Walworth'. Brain : a journal of neurology 105:1-28.
Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M (2004) Subtype selective substrates for histone deacetylases. Journal of medicinal chemistry 47:5235-5243.
Hendelman WJ, Aggerwal AS (1980) The Purkinje neuron: I. A Golgi study of its development in the mouse and in culture. The Journal of comparative neurology 193:1063-1079.
Hochheimer A, Tjian R (2003) Diversified transcription initiation complexes expand promoter selectivity and tissue-specific gene expression. Genes & development 17:1309-1320.
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 100:2041-2046.
Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d'Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN (2011) Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:11795-11807.
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458.
Ingram MA, Orr HT, Clark HB (2012) Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias. Brain research bulletin 88:33-42.
Jacobi H, Minnerop M, Klockgether T (2013) [The genetics of spinocerebellar ataxias]. Der Nervenarzt 84:137-142.
Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, Loidl P (1999) Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. Journal of medicinal chemistry 42:4669-4679.
Kalia SK, Kalia LV, McLean PJ (2010) Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS & neurological disorders drug targets 9:741-753.
Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American journal of translational research 3:166-179.
Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, Yamada M, Takahashi H, Tsuji S (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Human molecular genetics 8:2047-2053.
Kuo Y, Ren S, Lao U, Edgar BA, Wang T (2013) Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110. Cell death & disease 4:e833.
Li J, Shariff A, Wiking M, Lundberg E, Rohde GK, Murphy RF (2012) Estimating microtubule distributions from 2D immunofluorescence microscopy images reveals differences among human cultured cell lines. PloS one 7:e50292.
Liu J, Edagawa M, Goshima H, Inoue M, Yagita H, Liu Z, Kitajima S (2014) Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. Biochemical and biophysical research communications 445:320-326.
Maltecca F, Filla A, Castaldo I, Coppola G, Fragassi NA, Carella M, Bruni A, Cocozza S, Casari G, Servadio A, De Michele G (2003) Intergenerational instability and marked anticipation in SCA-17. Neurology 61:1441-1443.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nature reviews Cancer 1:194-202.
Matilla-Duenas A (2012) The ever expanding spinocerebellar ataxias. Editorial. Cerebellum 11:821-827.
Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP, Reed JC, Glinsky GV, Schimmer AD (2007) Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. Journal of the National Cancer Institute 99:811-822.
McKay BE, Turner RW (2005) Physiological and morphological development of the rat cerebellar Purkinje cell. The Journal of physiology 567:829-850.
Mohseni J, Zabidi-Hussin ZA, Sasongko TH (2013) Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genetics and molecular biology 36:299-307.
Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Human molecular genetics 10:1441-1448.
Nuutinen T, Suuronen T, Kyrylenko S, Huuskonen J, Salminen A (2005) Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochemistry international 47:528-538.
Ohira K, Funatsu N, Nakamura S, Hayashi M (2004) Expression of BDNF and TrkB receptor subtypes in the postnatal developing Purkinje cells of monkey cerebellum. Gene expression patterns : GEP 4:257-261.
Orr HT (2012) Cell biology of spinocerebellar ataxia. The Journal of cell biology 197:167-177.
Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317:516-519.
Popiel HA, Takeuchi T, Fujita H, Yamamoto K, Ito C, Yamane H, Muramatsu S, Toda T, Wada K, Nagai Y (2012) Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism. PloS one 7:e51069.
Riessland M, Brichta L, Hahnen E, Wirth B (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Human genetics 120:101-110.
Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, Schols L, Riess O (2003) Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Annals of neurology 54:367-375.
Romaniello R, Arrigoni F, Bassi MT, Borgatti R (2014) Mutations in alpha- and beta-tubulin encoding genes: Implications in brain malformations. Brain & development.
Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rub U (2012) Brain pathology of spinocerebellar ataxias. Acta neuropathologica 124:1-21.
Seipel K, Georgiev O, Gerber HP, Schaffner W (1994) Basal components of the transcription apparatus (RNA polymerase II, TATA-binding protein) contain activation domains: is the repetitive C-terminal domain (CTD) of RNA polymerase II a "portable enhancer domain"? Molecular reproduction and development 39:215-225.
Serrano-Munuera C, Corral-Juan M, Stevanin G, San Nicolas H, Roig C, Corral J, Campos B, de Jorge L, Morcillo-Suarez C, Navarro A, Forlani S, Durr A, Kulisevsky J, Brice A, Sanchez I, Volpini V, Matilla-Duenas A (2013) New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. JAMA neurology 70:764-771.
Sharma NL, Groselj B, Hamdy FC, Kiltie AE (2013) The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU international 111:537-542.
Shukla AK, Pragya P, Chaouhan HS, Tiwari AK, Patel DK, Abdin MZ, Chowdhuri DK (2014) Heat Shock Protein-70 (Hsp-70) Suppresses Paraquat-Induced Neurodegeneration by Inhibiting JNK and Caspase-3 Activation in Drosophila Model of Parkinson's Disease. PloS one 9:e98886.
Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M (2013) HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Molecular neurodegeneration 8:7.
Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31:537-551.
St Laurent R, O'Brien LM, Ahmad ST (2013) Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 246:382-390.
Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M (2012) Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Molecular neurobiology 46:430-466.
Tanaka M, Yanagawa Y, Hirashima N (2009) Transfer of small interfering RNA by single-cell electroporation in cerebellar cell cultures. Journal of neuroscience methods 178:80-86.
Tanaka M, Yanagawa Y, Obata K, Marunouchi T (2006) Dendritic morphogenesis of cerebellar Purkinje cells through extension and retraction revealed by long-term tracking of living cells in vitro. Neuroscience 141:663-674.
Torrente MP, Shorter J (2014) The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 7.
Villarreal A, Seoane R, Torres AG, Rosciszewski G, Angelo MF, Rossi A, Barker PA, Ramos AJ (2014) S100B protein activates a RAGE-dependent autocrine loop in astrocytes: Implications for its role in the propagation of reactive gliosis. Journal of neurochemistry.
Weisenberg RC (1972) Microtubule formation in vitro in solutions containing low calcium concentrations. Science 177:1104-1105.
Witt SN (2010) Hsp70 molecular chaperones and Parkinson's disease. Biopolymers 93:218-228.
Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD (2010) Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Molecular cancer therapeutics 9:246-256.
Yang H, Ganguly A, Cabral F (2010) Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. The Journal of biological chemistry 285:32242-32250.
Zhang X, Baader SL, Bian F, Muller W, Oberdick J (2001) High level Purkinje cell specific expression of green fluorescent protein in transgenic mice. Histochemistry and cell biology 115:455-464.